Assessment of cytochrome P450 (1A2, 2B6, 2C9 and 3A4) induction in cryopreserved human hepatocytes cultured in 48-well plates using the cocktail strategy

References

• Brown HS, Chadwick A, Houston JB. (2007). Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination. Drug Metab Dispos 35:2119–2126.
   PubMed Web of Science ®Google Scholar
• Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE. (2001). A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23–29.
   PubMed Web of Science ®Google Scholar
• Dixit V, Hariparsad N, Desai P, Unadkat JD. (2007). In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities. Biopharm Drug Dispos 28:257–262.
   PubMed Web of Science ®Google Scholar
• European Medecines Agency and Committee for Human Medicinal Products (CHMP). (2010). Guideline on the Investigation of Drug Interactions.
   Google Scholar
• Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM. (2000). Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222–1230.
   PubMed Web of Science ®Google Scholar
• Feidt DM, Klein K, Hofmann U, Riedmaier S, Knobeloch D, Thasler WE, Weiss TS, Schwab M, Zanger UM. (2010). Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes. Drug Metab Dispos 38:1589–1597.
   PubMed Web of Science ®Google Scholar
• Floby E, Briem S, Terelius Y, Sohlenius-Sternbeck AK. (2004). Use of a cocktail of probe substrates for drug-metabolizing enzymes for the assessment of the metabolic capacity of hepatocyte preparations. Xenobiotica 34:949–959.
   PubMed Web of Science ®Google Scholar
• Gerbal-Chaloin S, Pichard-Garcia L, Fabre JM, Sa-Cunha A, Poellinger L, Maurel P, Daujat-Chavanieu M. (2006). Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide Cell Signal 18:740–750.
   PubMed Web of Science ®Google Scholar
• Gómez-Lechón MJ, Lahoz A, Jiménez N, Vicente Castell J, Donato MT. (2006). Cryopreservation of rat, dog and human hepatocytes: influence of preculture and cryoprotectants on recovery, cytochrome P450 activities and induction upon thawing. Xenobiotica 36:457–472.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (2006). Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 8:E101–E111.
   PubMed Web of Science ®Google Scholar
• Hallifax D, Galetin A, Houston JB. (2008). Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines. Xenobiotica 38:353–367.
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Lecluyse EL, Ferguson SS. (2007). Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 37:1196–1224.
   PubMed Web of Science ®Google Scholar
• Huang S-M. (2012). Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations – Draft Guidance. CDER (Center for Drug Evaluation and Research) – FDA – http://www fda gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362 pdf
   Google Scholar
• Huang S-M, Stifano T. (2006). Guidance for Industry: Drug interaction studies - Study design, data analysis, and implications for dosing and labelling. Draft Guidance, September, 2006. http://www fda gov/cber/gdlns/interactstud htm
   Google Scholar
• Kafert-Kasting S, Alexandrova K, Barthold M, Laube B, Friedrich G, Arseniev L, Hengstler JG. (2006). Enzyme induction in cryopreserved human hepatocyte cultures. Toxicology 220:117–125.
   PubMed Web of Science ®Google Scholar
• Kanebratt KP, Andersson TB. (2008). Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36:1444–1452.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, Shin JG. (2005). High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2651–2658.
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Nakajima M, Oshima K, Shimada N, Yokoi T, Chiba K. (1999). Involvement of CYP2E1 as a low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos 27:860–865.
   PubMed Web of Science ®Google Scholar
• Lahoz A, Donato MT, Picazo L, Castell JV, Gómez-Lechón MJ. (2008). Assessment of cytochrome P450 induction in human hepatocytes using the cocktail strategy plus liquid chromatography tandem mass spectrometry. Drug Metab Lett 2:205–209.
   PubMedGoogle Scholar
• LeCluyse E, Madan A, Hamilton G, Carroll K, DeHaan R, Parkinson A. (2000). Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14:177–188.
   PubMed Web of Science ®Google Scholar
• LeCluyse EL. (2001). Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343–368.
   PubMed Web of Science ®Google Scholar
• Li AP. (2007). Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem Biol Interact 168:16–29.
   PubMed Web of Science ®Google Scholar
• Li AP, Kedderis GL. (1997). Primary hepatocyte culture as an experimental model for the evaluation of interactions between xenobiotics and drug-metabolizing enzymes. Chem Biol Interact 107:1–3.
   Google Scholar
• Lu C, Li AP. (2001). Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem Biol Interact 134:271–281.
   PubMed Web of Science ®Google Scholar
• MacDonald CJ, Ciolino HP, Yeh GC. (2004). The drug salicylamide is an antagonist of the aryl hydrocarbon receptor that inhibits signal transduction induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res 64:429–434.
   PubMed Web of Science ®Google Scholar
• Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner G, Yu L, Parkinson A. (2003). Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421–431.
   PubMed Web of Science ®Google Scholar
• Mandenius CF, Andersson TB, Alves PM, Batzl-Hartmann C, Björquist P, Carrondo MJ, Chesne C, Coecke S, Edsbagge J, Fredriksson JM, Gerlach JC, Heinzle E, Ingelman-Sundberg M, Johansson I, Küppers-Munther B, Müller-Vieira U, Noor F, Zeilinger K. (2011). Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines – a report on the Vitrocellomics EU-project. Altern Lab Anim 39:147–171.
   Google Scholar
• Mohutsky MA, Petullo DM, Wrighton SA. (2005). The use of a substrate cassette strategy to improve the capacity and throughput of cytochrome P450 induction studies in human hepatocytes. Drug Metab Dispos 33:920–923.
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ. (2001). Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268:6346–6358.
   PubMedGoogle Scholar
• Rae JM, Johnson MD, Lippman ME, Flockhart DA. (2001). Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299:849–857.
   PubMed Web of Science ®Google Scholar
• Richert L, Abadie C, Bonet A, Heyd B, Mantion G, Alexandre E, Bachellier P, Kingston S, Pattenden C, Illouz S, Dennison A, Hoffmann S, Coecke S. (2010). Inter-laboratory evaluation of the response of primary human hepatocyte cultures to model CYP inducers - a European Centre for Validation of Alternative Methods (ECVAM) - funded pre-validation study. Toxicol In Vitro 24:335–345.
   PubMed Web of Science ®Google Scholar
• Ring BJ, Patterson BE, Mitchell MI, Vandenbranden M, Gillespie J, Bedding AW, Jewell H, Payne CD, Forgue ST, Eckstein J, Wrighton SA, Phillips DL. (2005). Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo. Clin Pharmacol Ther 77:63–75.
   PubMed Web of Science ®Google Scholar
• Roymans D, Annaert P, Van Houdt J, Weygers A, Noukens J, Sensenhauser C, Silva J, Van Looveren C, Hendrickx J, Mannens G, Meuldermans W. (2005). Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab Dispos 33:1004–1016.
   PubMed Web of Science ®Google Scholar
• Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A. (2000). Bioanalytical method validation–a revisit with a decade of progress. Pharm Res 17:1551–1557.
   PubMedGoogle Scholar
• Testino SA Jr, Patonay G. (2003). High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 30:1459–1467.
   PubMed Web of Science ®Google Scholar
• Tolonen A, Petsalo A, Turpeinen M, Uusitalo J, Pelkonen O. (2007). In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. J Mass Spectrom 42:960–966.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. (1998). Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci 87:1502–1507.
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, Shader RI. (1996). Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology (Berl) 128:398–407.
   PubMed Web of Science ®Google Scholar
• Westerink WM, Schoonen WG. (2007). Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 21:1581–1591.
   PubMed Web of Science ®Google Scholar
• Zhang JG, Ho T, Callendrello AL, Crespi CL, Stresser DM. (2010). A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with β-naphthoflavone, phenobarbital and rifampicin Drug Metab Lett 4:185–194.
   PubMedGoogle Scholar
• Zuber R, Anzenbacherová E, Anzenbacher P. (2002). Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6:189–198.
   PubMed Web of Science ®Google Scholar